# Revatio Special Investigation for Long-term Use in Pediatric Patients

> **NCT03364244** · — · COMPLETED · sponsor: **Viatris Pharmaceuticals Japan Inc** · enrollment: 1023 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Sildenafil

## Key facts

- **NCT ID:** NCT03364244
- **Lead sponsor:** Viatris Pharmaceuticals Japan Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 1023 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364244, "Revatio Special Investigation for Long-term Use in Pediatric Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03364244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*